---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-325299"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:56:07.886468+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acumen posts presentation on ACU193 Phase 1 trial design for early Alzheimer's disease

## Summary
- ACU193 is a monoclonal antibody that selectively targets toxic amyloid-beta oligomers for early Alzheimer's disease.
- The Phase 1 INTERCEPT-AD trial design is detailed in the presentation posted on November 10, 2021.
- The presentation is available on Acumen's website and was furnished to the SEC as Exhibit 99.1.

## SEC filing metadata
- accession: 0001193125-21-325299
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312521325299/0001193125-21-325299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312521325299/d234985d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-325299
- JSON: https://secwatch.observer/filing/0001193125-21-325299.json
- Plain text: https://secwatch.observer/filing/0001193125-21-325299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.